Centrus Energy Corp.
LEU
$153.88
+8.80%
Centrus Energy Corp. supplies nuclear fuel and related services to the nuclear power industry, operating through a Low-Enriched Uranium (LEU) segment that sells separative work units (SWUs) and uranium, and a Technical Solutions segment providing engineering, design, and manufacturing services to government and private customers, with the vast majority of revenue generated in the United States. The company occupies a uniquely strategic position as the only U.S.-based producer of high-assay low-enriched uranium (HALEU), giving it a quasi-monopoly on a critical input for the next generation of advanced nuclear reactors. The current investor narrative centers on this HALEU franchise, a record $3.9 billion backlog, and roughly $900 million in government contracts tied to the AI-driven electricity demand boom, offset by persistent concerns over the pending expiration of legacy Russian supply contracts, execution risk on capacity expansion, and a stock that has fallen sharply from its highs. Recent news flow has been mixed but constructive, highlighted by a long-term fuel supply agreement with Oklo in June 2026 that directly addresses a major bottleneck in the U.S. advanced nuclear sector, while analyst commentary debates whether the recent sell-off has made the shares "too cheap to ignore."…
LEU
Centrus Energy Corp.
$153.88
Related headlines
Investment Opinion: Should I buy LEU Today?
Based on the synthesis of data, the recommendation is a Hold with a speculative tilt. The core thesis is that Centrus's unique HALEU monopoly and record $3.9 billion backlog provide substantial long-term upside, but near-term execution risks, cash burn, and margin compression warrant caution. The analyst consensus average target of $247.40 implies 77.6% upside, but the lack of a clear consensus rating and the prevalence of Neutral ratings suggest low conviction. The stock is trading near its 52-week low, which may attract value seekers, but the downtrend is still intact.
Supporting evidence for a Hold includes: 1) Revenue growth of 13.98% year-over-year in Q2 2026, though lumpy; 2) A fortress balance sheet with $1.9 billion in cash and a current ratio of 5.59; 3) The strategic Oklo agreement and $900 million in government contracts; and 4) The forward PE of 36.43x, which, while high, implies a forward PEG of 0.67 if earnings grow 54% as expected, suggesting potential undervaluation if growth materializes. However, these positives are offset by negative free cash flow of -$222.1 million, a debt-to-equity ratio of 1.59, and a stock that has underperformed the S&P 500 by 75.11 percentage points over the past year.
The biggest risks that could invalidate the thesis are: 1) Delays or cost overruns in HALEU expansion leading to further cash burn; 2) The expiration of Russian supply contracts disrupting the LEU segment; and 3) A breakdown below the 52-week low of $135.75 triggering momentum selling. The rating would upgrade to Buy if the stock stabilizes above $150 and HALEU revenue shows clear acceleration, or downgrade to Sell if free cash flow remains negative and the backlog fails to convert. Relative to its history, the stock is in the lower-middle portion of its valuation band, but it remains expensive on current earnings. It is fairly valued to slightly overvalued given the execution risks, but the long-term potential justifies a Hold for risk-tolerant investors.
Sign up to view all
LEU 12-Month Price Forecast
The 12-month outlook is balanced but with a neutral stance due to conflicting signals. The bull case hinges on successful HALEU execution and backlog conversion, which could drive the stock to $340, while the bear case reflects execution failures and cash burn, potentially pushing it to $100. The base case assumes steady progress and a re-rating to the analyst average of $247.40. Key factors include the unique HALEU monopoly, but also the severe downtrend and negative free cash flow. I would upgrade to bullish if HALEU revenue accelerates and free cash flow turns positive, and downgrade to bearish if the stock breaks below $135.75 or if the Russian contract expiration causes major disruption.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centrus Energy Corp.'s 12-month outlook, with a consensus price target around $247.40 and implied upside of +60.8% versus the current price.
Average Target
$247.40
0 analysts
Implied Upside
+60.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$169 - $340
Analyst target range
Centrus Energy is covered by 17 analysts, and the consensus average target price is $247.40, which implies substantial upside of approximately 77.6% from the current price of $139.27. The recommendation field is listed as "none," but the institutional ratings data shows a predominantly neutral-to-bullish tilt, with recent actions including Stifel reiterating Buy on August 25, 2026, Needham maintaining Buy on August 7, 2026, and Evercore ISI Group reiterating Outperform on the same date, while UBS, JP Morgan, B of A Securities, and Roth Capital have all maintained Neutral ratings. The consensus leans moderately bullish, with the buy-rated firms offset by a significant neutral contingent, reflecting both the compelling long-term HALEU story and near-term execution and valuation concerns.
The target price range is exceptionally wide, spanning from a low of $168.77 (still 21.2% above the current price) to a high of $340.00 (144.1% above current), a spread of $171.23 that signals high uncertainty and divergent views on the company's trajectory. The high target likely assumes successful HALEU capacity expansion, full backlog conversion, and multiple expansion as Centrus cements its monopoly position, while the low target prices in slower contract awards, margin compression, and the risk of Russian supply contract expiration disrupting the LEU segment. The fact that even the lowest analyst target is above the current price suggests the sell-off may have overshot fundamentals, but the wide dispersion and the prevalence of Neutral ratings indicate that conviction remains low and the stock is likely to stay volatile until clearer evidence of HALEU revenue acceleration emerges.
Bulls vs Bears: LEU Investment Factors
The bear case currently has stronger evidence due to the severe downtrend, negative free cash flow, and margin compression, which are concrete near-term headwinds. However, the bull case rests on a unique HALEU monopoly, a record $3.9 billion backlog, and substantial analyst upside, suggesting the sell-off may be overdone. The most important tension is whether the HALEU expansion and backlog conversion can accelerate revenue and reverse cash burn before the Russian contract expiration disrupts the legacy business. If HALEU execution succeeds, the stock could re-rate sharply; if not, further downside is likely. The market is pricing in significant skepticism, but the strategic value of Centrus's monopoly provides a floor for long-term investors.
Bullish
- HALEU Monopoly with Government Backing: Centrus is the only U.S.-based producer of high-assay low-enriched uranium (HALEU), a critical input for advanced nuclear reactors. This quasi-monopoly is reinforced by roughly $900 million in government contracts tied to the AI-driven electricity demand boom, providing a durable competitive moat and revenue visibility.
- Record $3.9B Backlog and Oklo Agreement: The company's backlog stands at a record $3.9 billion, and the June 2026 long-term fuel supply agreement with Oklo directly addresses a major bottleneck in the U.S. advanced nuclear sector. This agreement locks in future revenue and validates Centrus's strategic position in the HALEU supply chain.
- Analyst Targets Imply Significant Upside: The consensus average target price is $247.40, implying 77.6% upside from the current price of $139.27. Even the lowest analyst target of $168.77 is 21.2% above the current price, suggesting the recent sell-off may have overshot fundamentals.
- Fortress Balance Sheet with $1.9B Cash: Centrus ended Q2 2026 with $1.90 billion in cash and a current ratio of 5.59, providing substantial runway to fund its HALEU expansion without near-term financing risk. This liquidity supports the company's ability to execute on its growth initiatives despite negative free cash flow.
Bearish
- Severe Stock Downtrend and Underperformance: The stock is down 60.10% over the past year and 48.89% year-to-date, trading at just 1.07% of its 52-week range and only $3.52 above its 52-week low of $135.75. This persistent selling pressure and a maximum drawdown of -68.31% indicate deep market skepticism and a lack of near-term catalysts.
- Negative Free Cash Flow and Cash Burn: Trailing twelve-month free cash flow is -$222.1 million, driven by a Q2 2026 FCF of -$111.5 million that included $94.8 million in capital expenditures and a $92.5 million inventory build. The company is dependent on cash reserves and equity issuance (it raised $53.9 million in Q2 2026) to fund growth, which is unsustainable without a reversal.
- Margin Compression and Earnings Volatility: Q2 2026 net margin fell to 9.54% from 18.71% in Q2 2025, and gross margin compressed to 28.34% from 34.89% a year ago. The trailing PE of 56.06x is expensive on current earnings, and the wide gap between trailing and forward multiples signals vulnerability to any disappointment in the expected earnings inflection.
- Russian Supply Contract Expiration Risk: The pending expiration of legacy Russian supply contracts poses a significant risk to the LEU segment, which dominates revenue at $153.4 million in Q2 2026. Disruption could lead to revenue shortfalls and margin pressure, especially if alternative supply sources are not secured in time.
LEU Technical Analysis
Centrus Energy is in a pronounced downtrend, with the shares down 60.10% over the past year and 48.89% year-to-date, a stark reversal from the momentum that once carried the stock to a 52-week high of $464.25. At the current price of $139.27, the stock is trading at just 1.07% of its 52-week range (calculated as ($139.27 - $135.75) / ($464.25 - $135.75)), effectively pinned to its 52-week low of $135.75. This positioning near the bottom of the range signals a market that has aggressively de-rated the equity, and while it can present a value opportunity, the persistent selling pressure suggests caution against catching a falling knife until stabilization evidence emerges. The maximum drawdown of -68.31% underscores the severity of the decline from peak levels.
Short-term momentum remains decisively negative and is diverging bearishly from an already weak longer-term trend. The stock is down 18.79% over the past month and 14.10% over the past three months, meaning the recent decline is steeper than the 12-month trend, indicating accelerating selling pressure rather than a mere consolidation. Relative strength metrics confirm this underperformance: the stock has lagged the S&P 500 by 19.38 percentage points over one month and 75.11 percentage points over one year, a dramatic divergence from a benchmark that gained 15.01% over the same 12-month period. With a short ratio of 8.04 days, meaning it would take more than eight trading days of average volume to cover all short positions, there is meaningful bearish positioning that could fuel a sharp squeeze on any positive catalyst, though it equally reflects deep skepticism.
Key technical levels are clearly defined by the 52-week range: support sits at the $135.75 low, which is only $3.52 below the current price of $139.27, while resistance looms at the $464.25 high, a level more than 233% above current trading. A breakdown below $135.75 would likely trigger momentum-driven selling and open the door to new lows, whereas a sustained breakout above resistance would require a fundamental catalyst of enormous magnitude given the distance involved. The stock's beta of 1.334 indicates it is roughly 33% more volatile than the broader market, meaning position sizing should be conservative; a 1% move in the S&P 500 would historically correspond to a 1.33% move in LEU, amplifying both gains and losses for holders.
Beta
1.54
1.54x market volatility
Max Drawdown
-68.3%
Largest decline past year
52-Week Range
$136-$464
Price range past year
Annual Return
-56.8%
Cumulative gain past year
| Period | LEU Return | S&P 500 |
|---|---|---|
| 1m | -11.5% | +1.2% |
| 3m | -7.6% | +4.5% |
| 6m | -14.6% | +14.6% |
| 1y | -56.8% | +16.0% |
| ytd | -43.5% | +14.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LEU Fundamental Analysis
Centrus Energy's revenue trajectory is lumpy but growing, with the most recent quarter (Q2 2026) delivering $176.1 million in revenue, up 13.98% year-over-year from $154.5 million in Q2 2025. However, the multi-quarter trend reveals significant volatility: revenue rose from $76.7 million in Q1 2026 to $176.1 million in Q2 2026, but this followed a decline from $146.2 million in Q4 2025, reflecting the timing-dependent nature of SWU and uranium sales. Segment data shows the Product line (which includes SWUs and uranium) dominates at $153.4 million, with SWUs contributing $100 million and uranium $53.4 million, while services add $22.7 million; the heavy concentration in product sales means revenue is highly sensitive to contract timing and pricing. The investment case hinges on whether the record $3.9 billion backlog converts to revenue on schedule, as the current growth rate, while positive, does not yet reflect the step-change implied by the HALEU expansion.
Profitability is positive but under pressure, with Q2 2026 net income of $16.8 million and a net margin of 9.54%, down sharply from the 18.71% net margin in Q2 2025 when net income was $28.9 million. Gross margin in Q2 2026 came in at 28.34%, a compression from 34.89% in the year-ago quarter and well below the 38.72% recorded in Q1 2026, indicating margin volatility tied to product mix and cost of revenue. The trailing twelve-month gross margin of 26.19% and operating margin of 11.19% are respectable for the nuclear fuel industry but reflect the capital-intensive and contract-driven nature of the business. The company remains solidly profitable on a trailing basis with a net margin of 17.34%, but the recent quarterly trend of margin compression warrants monitoring, as it suggests either pricing pressure or higher input costs.
Centrus maintains a fortress-like liquidity position with a current ratio of 5.59 and $1.90 billion in cash at the end of Q2 2026, providing substantial runway to fund its HALEU expansion without near-term financing risk. However, the company is burning cash at an alarming rate, with trailing twelve-month free cash flow of -$222.1 million, driven by a Q2 2026 FCF of -$111.5 million that included $94.8 million in capital expenditures and a $92.5 million inventory build. The debt-to-equity ratio of 1.59 and debt ratio of 0.465 indicate moderate leverage, while the ROE of 10.17% and ROA of just 0.016% highlight that returns on the large asset base remain thin. The cash flow coverage ratio of -0.014 and negative operating cash flow of -$16.7 million in Q2 2026 underscore that the company is currently dependent on its cash reserves and equity issuance (it raised $53.9 million in Q2 2026) to fund growth, a dynamic that must reverse as HALEU production scales.
Quarterly Revenue
$176100000.0B
2026-06
Revenue YoY Growth
+14.0%
YoY Comparison
Gross Margin
28.3%
Latest Quarter
Free Cash Flow
$-222100000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LEU Overvalued?
Because Centrus Energy is profitable on a trailing basis with positive net income of $16.8 million in Q2 2026 and trailing EPS of $0.0178, the PE ratio is the appropriate primary metric, though the near-zero trailing EPS makes it less meaningful than the forward PE. The trailing PE stands at 56.06x, while the forward PE is 36.43x based on estimated EPS of $3.02, implying the market expects earnings to grow roughly 54% over the next year. This wide gap between trailing and forward multiples signals that investors are pricing in a significant earnings inflection, likely tied to HALEU contract ramp-up and backlog conversion, but it also means the stock is expensive on current earnings and vulnerable to any disappointment in that growth trajectory.
Relative to the broader Energy sector, Centrus trades at a substantial premium on most metrics: its price-to-sales ratio of 9.72x and price-to-book ratio of 5.70x are far above typical sector averages, and its EV/EBITDA of 32.97x is elevated for a company with volatile earnings. The PEG ratio of -15.73 is negative and therefore not meaningful given the distortion from near-zero trailing earnings, but the forward PE of 36.43x against an estimated earnings growth rate of roughly 54% implies a forward PEG of about 0.67, which would actually suggest undervaluation if that growth materializes. The premium is arguably justified by Centrus's unique HALEU monopoly and government backing, but it leaves little margin for error if execution slips.
Historically, Centrus's valuation has been extremely volatile, with the PE ratio ranging from 3.74x in Q4 2023 to 369.13x in Q3 2025, and the PS ratio swinging from 3.59x in Q2 2024 to 75.83x in Q3 2025. The current PS ratio of 9.72x is well below the Q3 2025 peak of 75.83x and the Q1 2026 level of 44.75x, but above the Q2 2024 trough of 3.59x, placing it in the lower-middle portion of its historical band. The current PB ratio of 5.70x is similarly below the Q3 2025 peak of 15.64x but above the Q2 2026 level of 3.95x, suggesting the market has de-rated the stock from its euphoric highs but has not yet priced it at deep-value levels, leaving room for further compression if fundamentals deteriorate.
PE
56.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 1x~65x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.0x
Enterprise Value Multiple
Investment Risk Disclosure
Centrus faces significant financial and operational risks, primarily stemming from its cash burn and margin volatility. Trailing twelve-month free cash flow is -$222.1 million, with Q2 2026 alone burning $111.5 million, driven by $94.8 million in capital expenditures and a $92.5 million inventory build. The company's debt-to-equity ratio of 1.59 and negative operating cash flow of -$16.7 million in Q2 2026 indicate reliance on cash reserves and equity issuance, which could strain liquidity if HALEU revenue does not ramp as expected. Additionally, revenue is highly concentrated in product sales ($153.4 million of $176.1 million in Q2 2026), making it sensitive to contract timing and pricing, while the pending expiration of Russian supply contracts threatens the LEU segment's stability.
Market and competitive risks are elevated due to the stock's extreme volatility and premium valuation. With a beta of 1.334, the shares are 33% more volatile than the broader market, and the stock has lagged the S&P 500 by 75.11 percentage points over the past year. The valuation remains rich, with a price-to-sales ratio of 9.72x and EV/EBITDA of 32.97x, leaving little margin for error if growth disappoints. Competitive threats could emerge if other companies enter the HALEU market or if government support wanes, though Centrus's first-mover advantage provides some protection. Recent news highlights the Oklo agreement as a positive, but also underscores execution risks and the need for sustained contract awards.
In a worst-case scenario, a failure to convert the $3.9 billion backlog into revenue on schedule, combined with the Russian contract expiration and continued cash burn, could trigger a sharp decline. The stock is already near its 52-week low of $135.75, and a breakdown below this level could lead to new lows, potentially testing the analyst low target of $168.77 (which is above current price) or lower if fundamentals deteriorate. From the current price of $139.27, a drop to the 52-week low represents a decline of about 2.5%, but if the stock revisits its historical max drawdown of -68.31% from the high, it could fall to around $147.50 (based on the 52-week high of $464.25), though that level is above current. A more realistic downside scenario might see the stock fall to $100-$120, representing a 14-28% loss, if HALEU delays and cash burn persist. Investors should be prepared for significant volatility given the beta and short ratio of 8.04 days.
FAQ
The key risks include: 1) Financial risk: negative free cash flow of -$222.1 million TTM and a debt-to-equity ratio of 1.59, which could strain liquidity if HALEU revenue does not ramp. 2) Execution risk: delays or cost overruns in HALEU expansion could prevent backlog conversion. 3) Contract risk: the expiration of Russian supply contracts could disrupt the LEU segment, which generated $153.4 million in Q2 2026. 4) Market risk: the stock has a beta of 1.334 and has underperformed the S&P 500 by 75.11 percentage points over the past year, making it vulnerable to further sell-offs. These risks are ranked from most to least severe, with financial and execution risks being the most immediate.
The 12-month forecast has three scenarios: bull case (25% probability) with a target range of $280-$340, driven by successful HALEU execution and new contracts; base case (50% probability) with a target range of $200-$250, assuming steady progress and analyst targets met; and bear case (25% probability) with a target range of $100-$135, reflecting execution failures and cash burn. The base case is most likely, hinging on HALEU revenue beginning to contribute meaningfully in late 2027 and the Russian contract expiration being managed without major disruption. The wide range reflects high uncertainty, and the stock is likely to remain volatile.
LEU's valuation is mixed. On a trailing basis, the PE of 56.06x and PS of 9.72x are elevated compared to the broader energy sector. However, the forward PE of 36.43x, based on estimated EPS of $3.02, implies a forward PEG of 0.67 if earnings grow 54%, which could suggest undervaluation if that growth materializes. The stock is trading below its historical peak PS of 75.83x but above its trough of 3.59x, placing it in the lower-middle of its historical band. The market is pricing in significant growth from HALEU, but the premium leaves little room for error. Relative to peers, it is expensive, but the unique monopoly may justify a premium.
Whether LEU is a good buy depends on your risk tolerance and time horizon. The stock trades at $139.27, near its 52-week low of $135.75, and analysts have an average target of $247.40, implying 77.6% upside. However, the company is burning cash (-$222.1 million TTM free cash flow) and faces execution risks on its HALEU expansion. The bull case rests on its unique monopoly and $3.9 billion backlog, while the bear case highlights margin compression and the Russian contract expiration. For long-term investors comfortable with volatility, the risk/reward may be attractive, but near-term uncertainty is high. It is not a suitable buy for conservative investors or those seeking income.
LEU is more suitable for long-term investment (minimum 3-5 years) given its early-stage HALEU growth story and the time needed for backlog conversion. The company pays no dividend, has a beta of 1.334, and earnings visibility is low due to contract timing. Short-term trading is risky due to the severe downtrend and high volatility, with the stock down 18.79% in the past month. Long-term investors can potentially benefit from the nuclear energy renaissance and Centrus's monopoly, but they must tolerate significant drawdowns. A suggested minimum holding period is 3 years to allow HALEU production to scale and cash flow to turn positive.